Preclinical studies suggest that exogenous surfactant may be of value in the treatment of the acute respiratory distress syndrome (ARDS), and two phase 2 clinical trials have shown a trend toward ...
Surfactant replacement therapy for respiratory distress syndrome (RDS) in preterm infants is a major breakthrough in neonatal medicine. Prophylactic or very early surfactant administration in very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results